Literature DB >> 698402

Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII.

U Seligsohn, B Osterud, S I Rapaport.   

Abstract

A coupled amidolytic assay for factor VII (VII) has been developed that when used with a clotting assay for VII enables detection of activated VII. In the assay, VII in a test material determines generation of factor Xa in a mixture of purified factor X, tissue factor, and calcium; factor Xa is measured with a chromogenic substrate. Factor VII activity in the coupled amidolytic assay (VIIam) correlated well with VII activity in a one-stage clotting assay (VIIc) in 57 healthy subjects, 5 patients with hereditary VII deficiency, and 11 patients with liver disease. Activation of plasma VII by kaolin, clotting, or cold strikingly increased VIIc but not VIIam levels. Thus the ratio VIIc/VIIam (VII activity ratio) is a measure of VII activation. In 27 warfarin-treated patients the mean VII activity ratio was significantly decreased, reflecting a greater decline in VIIc than in VIIam. This probably stems from partially carboxylated VII being able to act during the 3-min incubation of the amidolytic assay but unable to act rapidly enough to affect the clotting assay. Measurement of VIIc/VIIam should enable evaluation of the activity state of VII in thrombotic disorders and in components for transfusion therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698402

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin.

Authors:  M Pitsiu; E M Parker; L Aarons; B Holt; M Rowland
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII.

Authors:  U Seligsohn; B Osterud; S F Brown; J H Griffin; S I Rapaport
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

3.  Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.

Authors:  P Usharani; B J Warn-Cramer; C K Kasper; S P Bajaj
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

4.  Procoagulant activity of human neuroblastoma cell lines, in relation to cell growth, differentiation and cytogenetic abnormalities.

Authors:  N Esumi; S Imashuku; K Tsunamoto; S Todo; S Misawa; T Goto; Y Fujisawa
Journal:  Jpn J Cancer Res       Date:  1989-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.